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Abstract We previously reported that liposomalized 5P-O-
dipalmitoylphosphatidyl 2P-C-cyano-2P-deoxy-1-L-D-arabino-
pentofuranosylcytosine (DPP-CNDAC), a hydrophobized deri-
vative of the novel antitumor nucleoside CNDAC, is quite useful
for cancer therapy. On the other hand, for anti-neovascular
therapy, we recently isolated peptides homing to angiogenic
vessels from a phage-displayed random peptide library, and
observed that peptide-modified liposomal adriamycin strongly
suppressed tumor growth, perhaps through damaging angiogenic
endothelial cells. In the present study, we modified DPP-
CNDAC-liposomes with one of the angiogenic homing peptides,
APRPG, and examined their antitumor activity. Three doses of
APRPG-modified DPP-CNDAC-liposomes (15 mg/kg as
CNDAC) strongly inhibited tumor growth compared with the
same number of doses of unmodified DPP-CNDAC-liposomes.
The life span was increased 31.8%, with one completely cured
mouse out of the six mice treated. Since the accumulation of
liposomes in the tumor tissue was not so much different between
APRPG-liposomes and non-modified liposomes, the enhanced
therapeutic efficacy may be explained as the alteration of
targets, i.e. APRPG-modified DPP-CNDAC-liposomes caused
tumor growth suppression through damage of angiogenic
endothelial cells. Anti-neovascular therapy promises no drug
resistance, and should be effective against essentially any kind
of solid tumor; and thus the present results demonstrate another
benefit of the therapy, namely, high efficacy of cancer
treatment. 3 2002 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Tumor angiogenesis a¡ords new targets for cancer therapy,
since inhibition of angiogenesis causes tumor dormancy and
suppresses hematogenous metastases [1,2]. Besides anti-angio-
genic therapy, anti-neovascular therapy, i.e. the indirect lethal
damage to tumor cells through damage to neovessels, is also
being explored. Since anticancer drugs cause damage to grow-
ing cells, neovascular endothelial cells as well as tumor cells
are damaged by these drugs. In fact, cancer chemotherapy
using anti-neovascular scheduling induced endothelial cell ap-
optosis prior to tumor cell damage and e¡ectively eradicated
the tumor [3].
Liposomes are thought to be an ideal drug carrier in tar-
geted cancer chemotherapy. Liposomes have a tendency to
passively accumulate in tumor tissues due to their enhanced
permeability and retention e¡ect [4,5]. In addition, modi¢ca-
tion of liposomes with speci¢c ligands such as antibody, gly-
coconjugate, or oligopeptide enables active targeting of tumor
tissues [6,7] Especially, small peptides having high a⁄nity
against certain antigens are suitable for modi¢cation of lipo-
somes, since they are biocompatible, biodegradable, and less
antigenic compared to antibody and other modi¢ers. Further-
more, liposomalization of oligopeptides requires only a very
simple technique involving the use of a lipid derivative of an
oligopeptide that is easily synthesized and readily incorpo-
rated into the liposomal bilayer [8,9]. Thus we planned to
obtain oligopeptides speci¢c for angiogenic sites, and to mod-
ify liposomes with such a peptide for the purpose of develop-
ing an e¡ective drug carrier that would be applicable for anti-
neovascular therapy.
For this purpose, we recently isolated peptides speci¢c for
tumor angiogenic vasculature by using a phage-displayed pep-
tide library [10,11]. In vivo biopanning of phage-displayed
peptide library in angiogenic model mice prepared by the
dorsal air sac method [12] enabled us to isolate speci¢c phage
clones having the ability to bind only to angiogenic vessels,
not to tumor cells. After determination of the epitope sequen-
ces of the obtained phages and modi¢cation of liposomes with
these peptides, the APRPG-modi¢ed liposome was revealed to
be favorable for the active targeting of the angiogenic endo-
thelium. Furthermore, anti-neovascular therapy using this
type of liposome as a carrier of adriamycin markedly sup-
pressed tumor growth possibly through a cytotoxic e¡ect of
the drug against angiogenic endothelial cells [10], although an
increase in the local concentration of adriamycin released
from the liposomes may have partly contributed to this en-
hanced e⁄cacy.
In the present study, we investigated the therapeutic e⁄cacy
of APRPG-modi¢ed liposomes containing a lipophilic anti-
cancer drug, since such drugs would be expected to be deliv-
erable to the target cells in a liposomal form. Therefore, the
therapeutic e⁄cacy directly re£ects the destruction of the cells
to which the liposomes gain access. For this purpose, a lipo-
philic derivative of a novel anticancer drug 5P-O-dipalmitoyl-
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phosphatidyl 2P-C-cyano-2P-deoxy-1-L-D-arabino-pentofurano-
sylcytosine (DPP-CNDAC) was used. The mother compound
2P-C-cyano-2P-deoxy-1-L-D-arabino-pentofuranosylcytosine
(CNDAC) was originally synthesized by us as a novel anti-
tumor nucleoside antimetabolite, which induces DNA strand
breaks after its incorporation into tumor cell DNA [13,14].
Furthermore, 5P-phosphatidylation of the compound, i.e.
DPP-CNDAC [15], and its liposomal formulation [16,17] in-
dicated enhanced antitumor activity. Therefore, DPP-
CNDAC was thought to be favorable for liposomalization
and for anti-neovascular therapy using novel angiogenic ves-
sel-homing peptides.
2. Materials and methods
2.1. Materials
Synthesis of CNDAC and DPP-CNDAC was performed as de-
scribed previously [13,15]. A phosphatidyl group was introduced
into CNDAC through transphosphatidylation from 1,2-dipalmitoyl-
3-sn-glycerophosphocholine by using phospholipase D. APRPG pep-
tide was synthesized by use of Rink amide resin (0.4^0.7 mmol/g) and
a peptide synthesizer (ACT357; Advanced ChemTech, Louisville, KY,
USA), resulting in an amide at the carboxy-terminus. A stearoyl moi-
ety was introduced into the peptide by the DIPCI-HOBt coupling
method. Distearoylphosphatidylcholine (DSPC) was kindly supplied
by Dr. Yukihiro Namba of Nippon Fine Chemicals (Takasago, Hy-
ogo, Japan). Cholesterol was purchased from Sigma (St. Louis, MO,
USA).
2.2. Preparation of liposomes
DPP-CNDAC, DSPC, and cholesterol with or without stearoyl-
APRPG (10:10:5:2 or 10:10:5 molar ratio, respectively) dissolved
in chloroform were dried under reduced pressure and stored in vacuo
for at least 1 h. Liposomes were produced by hydration of the thin
lipid ¢lm with phosphate-bu¡ered glucose (pH 6.8) and freeze-thawed
for three cycles by use of liquid nitrogen. Then the liposomes were
sized by extrusion thrice through polycarbonate membrane ¢lters with
a 100-nm pore size (Nuclepore, Maidstone, UK). The liposomal so-
lutions were centrifuged at 180 000Ug for 20 min (Hitachi, CS120EX)
to remove the untrapped DPP-CNDAC if present. Then the lipo-
somes were resuspended in phosphate-bu¡ered glucose. For the deter-
mination of trapping e⁄cacy of DPP-CNDAC in the liposomes, an
aliquot of the liposomal solution was solubilized by the addition of
reduced Triton X-100, and the amount of DPP-CNDAC was optically
determined at 280 nm after the pH of the solution has been adjusted
to 1.0. For a biodistribution study, a trace amount of [oleate-1-
14C]cholesteryl-ether (74 kBq/mouse, Amersham Pharmacia, Bucking-
hamshire, UK) was added to the initial chloroform solution.
2.3. Biodistribution of liposomes
C26 NL-17 carcinoma cells were cultured in RPMI 1640 medium
(Nissui, Tokyo, Japan) containing 10% fetal bovine serum (Sigma).
After harvesting of the cells, 1.0U106 cells were carefully injected
subcutaneously into the posterior £ank of 5-week-old BALB/c male
mice (Japan SLC, Shizuoka, Japan). The biodistribution study was
performed when the tumor size had become about 10 mm in diameter.
Size-matched C26 NL-17 carcinoma-bearing mice were injected with
the radiolabeled liposomes via a tail vein. Three hours after the in-
jection, the mice were killed under diethyl ether anesthesia for the
collection of the blood which was centrifuged (600Ug for 5 min) to
obtain plasma. After the mice had been bled from the carotid artery,
the heart, lung, liver, spleen, kidney, and tumor were removed,
washed with saline, and weighed. The radioactivity in each organ
was determined with a liquid scintillation counter (Aloka, LSC-
3500). The animals were cared for according to the animal facility
guidelines of the University of Shizuoka.
2.4. Therapeutic experiment
Meth A sarcoma grown in the ascites of BALB/c mice under an
appropriate schedule was diluted with saline to obtain a suspension of
5U106 cells/ml. Then 0.2 ml of the suspension was carefully injected
subcutaneously into the posterior £ank of 5-week-old BALB/c male
mice (Japan SLC). Liposomes composed of DSPC, DPP-CNDAC,
cholesterol, and stearoyl-APRPG (10:10:5:2 molar ratio; APRPG-
LipCNDAC) or of DSPC, DPP-CNDAC, and cholesterol (10:10:5
molar ratio; LipCNDAC) were administered intravenously to Meth
A sarcoma-bearing mice at day 5, 9, and 13 after tumor implantation.
The amount of injected liposomes was 47.2 mg/kg/day as DPP-
CNDAC (15 mg/kg as CNDAC moiety). The size of the tumor and
body weight of each mouse were monitored daily thereafter. Two
bisecting diameters of each tumor were measured with slide calipers
to determine the tumor volume and calculation was performed using
the formula 0.4(aUb2), where a is the largest and b the smallest
diameter. The tumor volume thus calculated correlated well with the
actual tumor weight (r=0.980) [18].
2.5. Statistical analysis
Variance in a group was evaluated by the F-test, and di¡erences in
mean tumor volume were evaluated by Student’s t-test.
3. Results
3.1. Biodistribution of APRPG-modi¢ed DPP-CNDAC
liposomes
Previously, we demonstrated that APRPG-modi¢ed lipo-
somes accumulated more in tumor tissues than peptide-un-
modi¢ed ones [10]. However, since DPP-CNDAC was incor-
porated into the lipid bilayer of the liposomes, the CNDAC
moiety on the liposomal surface may a¡ect the targeting char-
acter of APRPG-liposomes. Therefore, ¢rstly the e¡ects of
DPP-CNDAC incorporation on the biodistribution of
APRPG-modi¢ed liposomes were examined. As shown in
Fig. 1, the distribution of APRPG-LipCNDAC was not so
very di¡erent from that of LipCNDAC, although APRPG-
LipCNDAC accumulated in the tumor tissue a little more
than LipCNDAC. Therefore, DPP-CNDAC may a¡ect the
Fig. 1. Biodistribution of APRPG-LipCNDAC. Liposomes were
prepared and labeled as described in Section 2. Size-matched C26
NL-17 carcinoma-bearing mice were injected with LipCNDAC
(open bar) or APRPG-LipCNDAC (closed bar) via a tail vein.
Three hours after the injection, the mice were killed under diethyl
ether anesthesia, and the organs were removed. The radioactivity in
each organ was determined in a liquid scintillation counter. Data
are presented as the percentage of the injected dose per g tissue and
S.D. in each tissue (in the case of plasma, value was per ml instead
of per gram). The radioactivities of cholesteryl [14C]oleate are
shown.
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in vivo behavior of APRPG-modi¢ed liposomes and reduce
their targeting character. However, this characteristic was not
fully abolished by the incorporation of this amount of DPP-
CNDAC into the liposomes.
3.2. Therapeutic e⁄cacy of APRPG-modi¢ed DPP-CNDAC
liposome
Next, the antitumor activities of LipCNDAC and APRPG-
LipCNDAC were examined. In this experiment, Meth A sar-
coma-bearing mice were used instead of C26 NL-17 carcino-
ma-bearing ones, since Meth A sarcoma cells form a round
tumor after subcutaneous injection, thus a¡ording a more
accurate determination of tumor volume.
As shown in Fig. 2, APRPG-LipCNDAC showed the most
potent suppression of tumor growth (signi¢cantly di¡erent
from the control, P6 0.001, and from the LipCNDAC treat-
ment, P6 0.05, for the data points of day 19). Concerning the
side e¡ects, both liposomal formulations of DPP-CNDAC
induced a slight and transient reduction in the body weight
that was reversed within a few days (data not shown). The
survival time of these mice is shown in Fig. 3. The mean
survival time of control, LipCNDAC-treated, and APRPG-
LipCNDAC-treated groups was 30.5, 32.2, and 40.2 days,
respectively; thus the increase in survival was 5.5% for the
LipCNDAC-treated group and 31.8% for the APRPG-
LipCNDAC-treated group. Furthermore, one out of the six
mice was completely cured by the treatment with APRPG-
LipCNDAC. These data indicate that APRPG modi¢cation
enhanced the antitumor activity of the DPP-CNDAC lipo-
somes. Since the drug distribution to the tumor was not so
very di¡erent between the two types of liposomes, the e¡ect of
APRPG modi¢cation might not have been due to an in-
creased amount of DPP-CNDAC in the tumor tissue but
rather to a topological change in the delivered DPP-CNDAC,
i.e. APRPG-LipCNDAC may have delivered more DPP-
CNDAC to angiogenic endothelial cells, the damage to which
would be more serious for the survival of the tumor cells.
4. Discussion
If a drug could be delivered to only the desired site in the
correct concentration at the right time, we could expect a
more bene¢cial therapeutic e¡ect of the drug, especially for
drugs having severe side e¡ects such as anticancer drugs.
Liposomes have been used to prolong the circulation time
of such drugs, to deliver them to the target, namely, tumor
tissue, and to reduce side e¡ects [19]. Among active targeting
strategies, vascular targeting has become an issue of recent
interest, since anticancer drugs or drug-carrying liposomes
¢rst meet angiogenic vessels before extravasation into the tu-
mor tissue. Since these vessels have properties di¡erent from
those of the preexisting systemic vasculature [20,21], it is pos-
sible to develop a probe speci¢c for the neovasculature. Fur-
thermore, anti-neovascular therapy, i.e. the therapy for indi-
rect tumor cell killing through cutting o¡ the supply of oxygen
and nutrients to tumor cells by direct destruction of angio-
genic endothelial cells, should be achievable by vascular tar-
geting.
For the purpose of vascular targeting, we recently isolated
peptide probes speci¢c for neovasculature by using a phage-
displayed random peptide library [10,11]. Thus obtained
WRP-containing peptides showed anti-angiogenic activity.
Another peptide, a pentadecapeptide containing an APRPG
sequence, did not show such anti-angiogenic activity; how-
ever, it strongly bound to angiogenic endothelial cells as de-
termined by histochemical analysis using human islet cell tu-
Fig. 2. Suppression of tumor growth by APRPG-LipCNDAC in
Meth A sarcoma-bearing mice. Meth A sarcoma-bearing BALB/c
mice (n=6) were injected i.v. with 0.3 M phosphate-bu¡ered glucose
(open circle), LipCNDAC (closed circle), or APRPG-LipCNDAC
(closed square). The weight of each mouse, an indicator of side ef-
fects, and size of the tumor were monitored every day after initia-
tion of administration. Data are presented as the mean tumor vol-
ume and S.D. The S.D. bars are shown only for the last points for
the sake of graphic clarity. Arrows show the days of treatment. Sig-
ni¢cant di¡erences are indicated (*P6 0.05; **P6 0.001).
Fig. 3. Elongation of survival time of tumor-bearing mice treated
with APRPG-LipCNDAC. Mice (n=6) were implanted subcutane-
ously with Meth A sarcoma into the left posterior £ank. At 6, 10,
and 14 days after tumor implantation, they were injected intrave-
nously with 0.3 M glucose (open circle), LipCNDAC (closed circle),
or APRPG-LipCNDAC (closed square).
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mor of the pancreas and glioblastoma specimens. The histo-
chemical analysis also indicated that this pentadecapeptide did
not interact with tumor cells. Furthermore, confocal micro-
scopic observation indicated that APRPG-modi¢ed liposomes
speci¢cally bound to vascular endothelial growth factor-
stimulated human umbilical vein endothelial cells, for the
binding was cancelled by the addition of APRPG peptide
[10]. In fact, APRPG-modi¢ed liposomes showed about
three-fold higher accumulation in tumor tissues of tumor-
bearing mice than non-modi¢ed ones, and APRPG-modi¢ed
liposomes entrapping adriamycin strongly suppressed the tu-
mor growth of tumor-bearing mice [10]. This enhanced anti-
tumor activity of these liposomes may be explained by the
e⁄cient destruction of neovascular endothelial cells through
active targeting of the drug to the cells, although an increase
in the local concentration of adriamycin would also partly
contribute to the enhancement.
In the present study, we applied these APRPG-modi¢ed
liposomes for anti-neovascular therapy by using a lipophilic
derivative of an anticancer drug, DPP-CNDAC. Since lipo-
philic drugs should be delivered to the cells in a liposomal
form, the therapeutic e⁄cacy should re£ect the damage to
the cells to which the liposomes gain access rather than a
change in the local concentration of the agent in the tumor
tissue. If the therapeutic e⁄cacy of APRPG-liposomal DPP-
CNDAC is superior to that of non-modi¢ed liposomal DPP-
CNDAC, such a result would suggest that the destruction of
angiogenic endothelial cells is superior to the direct destruc-
tion of tumor cells for e¡ective tumor treatment, and vice
versa. Our present results indicate that the delivery of DPP-
CNDAC to angiogenic endothelial cells is, in fact, far superior
for the suppression of tumor growth.
A previous study demonstrated that DPP-CNDAC incor-
porated into long-circulating liposomes showed enhanced ac-
tivities for reducing tumor growth and increasing the lifetime
of the mice compared to conventional liposomes or soluble
CNDAC [16]. In that study, the long-circulating property was
achieved by modi¢cation of the liposomes with palmityl-D-
glucuronide, and the enhanced therapeutic e⁄cacy might
have been due to the passive targeting e¡ect of long-circulat-
ing liposomes. In other words, the topical concentration of
DPP-CNDAC in the tumor was increased in the form of lipo-
somes without the change in target cells. The tumor model
and doses of DPP-CNDAC were the same between the former
and present experiments, although the treatment schedule was
not completely the same. The enhanced therapeutic e⁄cacy,
however, was much higher in the present study than in the
former one. This di¡erence can be explained by the fact that
the liposomal long-circulating character results in a quantita-
tive di¡erence in DPP-CNDAC in the tumor tissue, whereas
liposomal APRPG modi¢cation causes a qualitative di¡er-
ence, namely, tumor growth suppression through damaging
angiogenic endothelial cells. In fact, the bulk accumulation
of liposomes in the tumor tissue was not so very di¡erent
between the APRPG-liposomes and non-modi¢ed ones
(Fig. 1).
Taken together, the available data indicate that anti-neo-
vascular therapy is an e⁄cient modality for cancer treatment
and that APRPG modi¢cation is useful for anti-neovascular
therapy. The APRPG-liposome is able to deliver not only
anticancer agents for anti-neovascular therapy, but also
anti-angiogenic agents for tumor dormancy therapy. Direct
conjugation of the peptide with anticancer agents or angio-
genesis inhibitors would also be a hopeful approach.
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